Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jeffrey Cook

Interventional Cardiology Quincy, IL Medical Doctor

NPI 1952353518 CMS profile 361553

927 Broadway St, Ste 230, Quincy, IL 62301

Open in the dashboard

General payments

$20,081

298 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jeffrey Cook of Quincy, IL is reported in the CMS Open Payments database as having received $20,081 across 298 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 75th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,434 48
2024 General $8,564 52
2023 General $3,647 43
2022 General $851 31
2021 General $1,104 44
2020 General $496 18
2019 General $1,984 62

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jeffrey Cook
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Jeffrey Cook were reported at $3,434. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Jeffrey Cook Interventional Cardiology median Middle half National median
2019 $1,984 $1,097 $329–$3,048 $163
2020 $496 $473 $161–$1,480 $114
2021 $1,104 $677 $233–$1,827 $132
2022 $851 $978 $333–$2,724 $149
2023 $3,647 $1,136 $382–$2,986 $160
2024 $8,564 $1,181 $395–$3,326 $164
2025 $3,434 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $10,738 74 payments
  2. Edwards Lifesciences Corporation $3,478 20 payments
  3. Abbott Laboratories $1,907 49 payments
  4. Medtronic Vascular, Inc. $1,370 30 payments
  5. Shockwave Medical, Inc $381 19 payments
  6. Boston Scientific Corporation $322 14 payments
  7. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $294 22 payments
  8. Novartis Pharmaceuticals Corporation $233 11 payments
  9. Abiomed $212 5 payments
  10. AstraZeneca Pharmaceuticals LP $160 11 payments
  11. Other $987 43 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $12,715 27 payments
  2. Food and Beverage $7,353 270 payments
  3. Education $14 1 payment
Products named General payments · program years 2019–2025
  1. COREVALVE EVOLUT R $9,213 51 payments
  2. EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) $2,885 11 payments
  3. CoreValve Evolut Transcatheter Valve Systems $1,246 19 payments
  4. TRICLIP $1,059 9 payments
  5. Edwards SAPIEN 3 Ultra Transcatheter Heart Valve $439 7 payments
  6. CoreValve Evolut Transcatheter Valve Systems $337 8 payments
  7. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter $326 16 payments
  8. LifeVest $294 22 payments
  9. Indigo $231 2 payments
  10. Impella $212 5 payments
  11. Other $3,373 167 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 56 drugs

Part D claims

4,952

Median for Interventional Cardiology: 2,236

Drug cost

$605,909

Median for Interventional Cardiology: $380,412

Branded share of claims

24.8%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 280 $295,847
Xarelto Rivaroxaban Brand 99 $109,238
Entresto Sacubitril/Valsartan Brand 53 $47,674
Multaq Dronedarone Hcl Brand 20 $36,106
Repatha Sureclick Evolocumab Brand 46 $35,733
Praluent Pen Alirocumab Brand 14 $11,689
Prasugrel Hcl Generic 56 $7,896
Corlanor Ivabradine Hcl Brand 13 $7,795
Jardiance Empagliflozin Brand 11 $7,357
Ranolazine Er Ranolazine Brand 30 $5,788

The 10 drugs with the highest cost, of 56 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 92 billing codes

Paid by Medicare

$205,776

Of which drugs: $867

Medicare patients

1,505

Average age 75

Services billed

3,063

738 women, 767 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 57%
Arthritis 53%
Atrial fibrillation 43%
Diabetes 42%
Heart failure 40%
Chronic kidney disease 39%
COPD 34%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, perflutren lipid microspheres, per ml Q9957 Office 13 26 $856

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VERQUVO
  • Merck Sharp & Dohme Corporation $26
$26 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $24
$24 — —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $24
$24 53 —
ELIQUIS
  • PFIZER INC. $18
$18 280 —
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $15
$15 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

298 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record